Opthalmic Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : May-2020 | List of Tables : 55 | List of Figures : 90 | No. of Pages : 170 | Report Code : FACT4799MR | Format :

Global Ophthalmic Drugs Market Overview:

The global ophthalmic drugs market shall gain moderate traction during the forecast period (2020-2025), registering a CAGR of 4.2%. There is an increase in incidences of eye-related diseases, particularly in developing nations, over the past several years. Visual impairment is a global health concern having a negative impact on physical and mental health. The increasing patient pool of visually impaired is anticipated to boost demand for healthcare spending on ophthalmology drugs.

Global Ophthalmic Drugs Market Trends:

The number of FDA approvals for advanced therapeutics is rising. Consequently, demand for advanced ophthalmology drugs is burgeoning. For instance, in 2016, Shire introduced Xiidra, a lymphocyte function associated antigen-1 (LFA-1) antagonist for ophthalmic drugs disorders. The foremost trend in ophthalmic drugs is the attainment of adequate drug concentrations at the targeted part of the eye with minimal side effects. This rising pool of ophthalmology patients, coupled with increasing approvals for the launch of therapeutic drugs is anticipated to leverage the global ophthalmology drugs market.

Global Ophthalmic Drugs Market: By Disease-Indication:

Retinal disorders are anticipated to find major application for ophthalmic drugs, holding more than one-third of the global ophthalmology drugs market, expanding at a CAGR of 4.7% during the forecast period. The glaucoma segment is poised to capture more than two-fifths of the overall ophthalmic drugs market, expanding stagnantly at a CAGR of 3.5%.

global ophthalmic drugs market value and growth forecast by disease indication

To get the latest COVID-19 impact insights on the ophthalmic drugs market, ask an analyst here

Increasing patient pool acquiring retinal problems is a key driver augmenting growth of the retinal disorders segment. According to sources, the number of patients with age-related macular degeneration (AMD) is anticipated to rise to 288 million by 2040. Rising pool of glaucoma patients and presence of key market players like Pfizer, Inc., Novartis AG and Valeant Pharmaceuticals International, Inc. manufacturing important drugs and formulations are anticipated to leverage market share of glaucoma drugs.

Global Ophthalmic Drugs Market: Regional Insights:

North America is poised to capture a majority of the global ophthalmic drugs market share (~2/5th) while the Asia-Pacific region is anticipated to expand at a CAGR of 4.9% during the forecast period. High cost of prescription drugs and the presence of key market players such as shall burgeon the North American ophthalmic drugs market.

global ophthalmic drugs market by region

To get in-depth regional insights on the ophthalmic drugs market, request for a report sample here

Increasing investments by major market players and research institutes for innovations in the ophthalmic space are key growth drivers of the Asia-Pacific. There is immense government support regarding funding of research institutions to facilitate studies in ophthalmic drugs.

Opthalmic Drug Market Manufacturers

The global ophthalmic drugs market is consolidated. The top four players constitute more than three-fifths of the market. These players are Novartis AG, Regeneron Pharmaceuticals, Inc., ALLERGAN and Santen Pharmaceutical Co., Ltd. These companies primarily concentrate on developing new drugs and innovating their development formula.

For example, Santen Pharmaceutical Co. and Singapore Eye Research Institute announced a strategic, five-year extended collaboration to develop new technologies for unmet medical needs in key ophthalmic drugs domains in 2017. The company manufactures prescription drugs for corneal, retinal and glaucoma diseases, which include Diquas, Tapros, Alesion and Eylea. Novartis AG, another player, integrates new products into its existing pipeline of drugs. It specializes in innovative medicines and includes ophthalmic drugs   products like Lucentis and Travoprost.

COVID-19’s Impact on the Ophthalmic Drugs Market:

The outbreak of the coronavirus disease has presented credible opportunities for the expansion of the ophthalmic drugs market. There have been multiple reports about eye redness and irritation in COVID-19 patients, suggesting that conjunctivitis could be an ocular manifestation of COVID-19 infection. It was concluded in 2003 during the outbreak of SARS that lack of eye protection was the primary cause of transmission of the virus. A similar trend has been observed in the current wave of infections. However, most ocular manifestation of COVID-19 are self-limited and can be managed with symptomatic care.

With several countries easing social distancing measures, the supply chain of ophthalmic drugs market is anticipated to function normally. In light of the abovementioned trends, hospitals and other healthcare settings will demand increased quantities of ophthalmic drugs as a precautionary measure. With the logistical arrangements reverting to normal, availability of such drugs will become much easier. Moreover, leading manufacturers have been increasing their productive capacities and are optimistic about registering an uptick in their operations in the wake of the easing of restrictions.

Analyst’s Viewpoint:

“Rising prevalence of visual impairments has prompted healthcare providers to accelerate ophthalmic treatment across the world. This has motivated market players to develop important drugs, thereby leveraging prospects of the global ophthalmic drugs market. North America and Asia-Pacific shall generate the largest demand for ophthalmic drugs in the future.”

Global Ophthalmic Drugs Market: Report Scope:

The recent study undertaken by Fact.MR on the global ophthalmic drugs market provides a 5-year forecast period ranging from 2020 to 2025 and explicates on key dynamics impacting the market’s growth such as the drivers, opportunities and restraints. The ophthalmic drugs market has been analyzed in detail, providing information on the revenue, market share and yearly growth opportunities. Moreover, the market has been segmented based on disease indication, therapeutic class, product type and distribution channels.

The report also includes a detailed regional landscape based on the following geographies: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Each regional profile incorporates the abovementioned segments. Towards the end, a competition landscape has also been given. In this section, key companies’ revenue and market shares, product launches and important collaborations with other players have been provided. In order to provide a realistic outlook, each company is also provided with a SWOT analysis.

Global Ophthalmic Drugs Market- Scope of the Report

The recent study by Fact.MR on global ophthalmic drugs market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends that are currently determining the growth of the global ophthalmic drugs market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of ophthalmic drugs. The study also provides dynamics that are responsible for influencing the future status of the global ophthalmic drugs market over the forecast period.

A detailed assessment of the global ophthalmic drugs market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global ophthalmic drugs market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Ophthalmic Drugs Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global ophthalmic drugs market across the globe.

A comprehensive estimate of the global ophthalmic drugs market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global ophthalmic drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Global Ophthalmic Drugs Market Segmentation

Fact.MR has studied the global ophthalmic drugs market with detailed segmentation on the basis of disease indication, therapeutic class, product type, distribution channels and regions.

Disease Indication

Therapeutic Class

Product Type

Distribution Channels

Region

Dry Eye

Anti-inflammatory Drugs:

NSAIDs

Steroids

Prescription Drugs

Hospital Pharmacies

North America

Glaucoma

Anti-infective Drugs:

Anti-fungal Drugs

Anti-bacterial Drugs

Others

OTC Drugs

Online Pharmacies

Europe

Infection/Inflammation

Anti-glaucoma Drugs:

Alpha Agonist

Beta Blockers

Prostaglandin Analogs

Combined Medication

Others

 

Independent Pharmacies & Drug Stores

Asia Pacific

Retinal Disorders:

Wet AMD

Dry AMD

Diabetic Retinopathy

Others

Anti-allergy Drugs

 

 

Latin America

Allergy

Anti-VEGF Drugs

 

 

Middle East & Africa (MEA)

Uveitis

Others

 

 

 

Others

 

 

 

 

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Ophthalmic Drugs Market: Analysis on Market Size Evaluation

The global ophthalmic drugs market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for ophthalmic drugs is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent ophthalmic drugs market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Ophthalmic Drugs Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global ophthalmic drugs report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the global ophthalmic drugs market during the forecast period.

Country-specific valuation on demand for ophthalmic drugs has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

Global Ophthalmic Drugs Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global ophthalmic drugs   along with their detailed profiles. Essential and up-to-date data and information related to the market performers, who are principally engaged in the production of ophthalmic drugs, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global ophthalmic drugs market. Prominent manufacturers with established market presence in the global ophthalmic drugs market are Allergen, Bausch & Lomb Incorporated (Valeant Pharmaceuticals International, Inc.), Genentech, Inc., (F. Hoffmann- La Roche Ltd.), Novartis AG, Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, Inc., Bayer AG, Pfizer, Inc., to name a few.  

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ophthalmic Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Disease Indication Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Key Market Indicators

    4.4. Market Dynamics

        4.4.1. Drivers

        4.4.2. Restraints

        4.4.3. Opportunity

        4.4.4. Trends

    4.5. Global Ophthalmic Drugs Market Analysis and Forecasts, 2020–2025

        4.5.1. Market Revenue Projections (US$ Mn)

    4.6. Porter’s Five Force Analysis

    4.7. Market Outlook

    4.8. Global Company Share Analysis: Glaucoma; 2018

    4.9. Pipeline Analysis: Major Market Players

    4.10. Pipeline Analysis: Emerging Market Players

    4.11. Comparison matrix for product offerings: Major Market Players

    4.12. Snapshot: Causes of blindness - Global

    4.13. Snapshot: Causes of blindness - Regional

5. Global Ophthalmic Drugs Market Analysis and Forecasts, By Disease Indication 

    5.1. Introduction & Definition

    5.2. Key Findings / Developments

    5.3. Key Trends

    5.4. Market Value Forecast by Disease Indication, 2020–2025

        5.4.1.  Dry Eye

        5.4.2.  Glaucoma

        5.4.3.  Infection/Inflammation

        5.4.4.  Retinal Disorders

            5.4.4.1. Wet AMD

            5.4.4.2. Dry AMD

            5.4.4.3. Diabetic Retinopathy

            5.4.4.4. Others

        5.4.5.  Allergy

        5.4.6.  Uveitis

        5.4.7.  Others

    5.5. Market Attractiveness by Disease Indication 

6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Therapeutic Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Key Trends

    6.4. Market Value Forecast By Therapeutic Class, 2020–2025

        6.4.1.  Anti-inflammatory Drugs

            6.4.1.1. NSAID

            6.4.1.2. Steroids

        6.4.2.  Anti-infective Drugs

            6.4.2.1. Anti-fungal Drugs

            6.4.2.2. Anti-bacterial Drugs

            6.4.2.3. Others

        6.4.3.  Anti-glaucoma Drugs

            6.4.3.1. Alpha Agonist

            6.4.3.2. Beta Blockers

            6.4.3.3. Prostaglandin Analogs

            6.4.3.4. Combined Medication

            6.4.3.5. Others

        6.4.4.  Anti-allergy Drugs

        6.4.5.  Anti-VEGF Agents

        6.4.6.  Others

    6.5. Market Attractiveness by Therapeutic Class 

7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Key Trends

    7.4. Market Value Forecast by Product Type, 2020–2025

        7.4.1.  Prescription Drugs

        7.4.2.  OTC Drugs

    7.5. Market Attractiveness by Product Type 

8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channels 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Key Trends

    8.4. Market Value Forecast by Distribution Channels, 2020–2025

        8.4.1.  Hospital Pharmacies

        8.4.2.  Online Pharmacies

        8.4.3.  Independent Pharmacies & Drug Stores

    8.5. Market Attractiveness by Distribution Channels 

9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region

    9.1. Key Findings

    9.2. Policies and Regulations

    9.3. Market Value Forecast by Region

        9.3.1.  North America 

        9.3.2.  Europe 

        9.3.3.  Asia Pacific 

        9.3.4.  Latin America 

        9.3.5.  Middle East and Africa 

    9.4. Market Attractiveness by Country/Region

10. North America Ophthalmic Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

        10.1.2. Policies and Regulations

        10.1.3. Key Trends

    10.2. Market Value Forecast by Disease Indication, 2020–2025

        10.2.1. Dry Eye

        10.2.2. Glaucoma

        10.2.3. Infection/Inflammation

        10.2.4. Retinal Disorders

            10.2.4.1. Wet AMD

            10.2.4.2. Dry AMD

            10.2.4.3. Diabetic Retinopathy

            10.2.4.4. Others

        10.2.5. Allergy

        10.2.6. Uveitis

        10.2.7. Others

    10.3. Market Value Forecast by Therapeutic Class, 2020–2025

        10.3.1. Anti-inflammatory Drugs

            10.3.1.1. NSAID

            10.3.1.2. Steroids

        10.3.2. Anti-infective Drugs

            10.3.2.1. Anti-fungal Drugs

            10.3.2.2. Anti-bacterial Drugs

            10.3.2.3. Others

        10.3.3. Anti-glaucoma Drugs

            10.3.3.1. Alpha Agonist

            10.3.3.2. Beta Blockers

            10.3.3.3. Prostaglandin Analogs

            10.3.3.4. Combined Medication

            10.3.3.5. Others

        10.3.4. Anti-allergy Drugs

        10.3.5. Anti-VEGF Agents

        10.3.6. Others

    10.4. Market Value Forecast by Product Type, 2020–2025

        10.4.1. Prescription Drugs

        10.4.2. OTC Drugs

    10.5. Market Value Forecast by Distribution Channels, 2020–2025

        10.5.1. Hospital Pharmacies

        10.5.2. Online Pharmacies

        10.5.3. Independent Pharmacies & Drug Stores

    10.6. Market Value Forecast by Country, 2020–2025

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis 

        10.7.1. By Disease Indication 

        10.7.2. By Therapeutic Class 

        10.7.3. By Product Type 

        10.7.4. By Distribution Channels 

        10.7.5. By Country

11. Europe Ophthalmic Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

        11.1.2. Policies and Regulations

        11.1.3. Key Trends

    11.2. Market Value Forecast by Disease Indication, 2020–2025

        11.2.1. Dry Eye

        11.2.2. Glaucoma

        11.2.3. Infection/Inflammation

        11.2.4. Retinal Disorders

            11.2.4.1. Wet AMD

            11.2.4.2. Dry AMD

            11.2.4.3. Diabetic Retinopathy

            11.2.4.4. Others

        11.2.5. Allergy

        11.2.6. Uveitis

        11.2.7. Others

    11.3. Market Value Forecast by Therapeutic Class, 2020–2025

        11.3.1. Anti-inflammatory Drugs

            11.3.1.1. NSAID

            11.3.1.2. Steroids

        11.3.2. Anti-infective Drugs

            11.3.2.1. Anti-fungal Drugs

            11.3.2.2. Anti-bacterial Drugs

            11.3.2.3. Others

        11.3.3. Anti-glaucoma Drugs

            11.3.3.1. Alpha Agonist

            11.3.3.2. Beta Blockers

            11.3.3.3. Prostaglandin Analogs

            11.3.3.4. Combined Medication

            11.3.3.5. Others

        11.3.4. Anti-allergy Drugs

        11.3.5. Anti-VEGF Agents

        11.3.6. Others

    11.4. Market Value Forecast by Product Type, 2020–2025

        11.4.1. Prescription Drugs

        11.4.2. OTC Drugs

    11.5. Market Value Forecast by Distribution Channels, 2020–2025

        11.5.1. Hospital Pharmacies

        11.5.2. Online Pharmacies

        11.5.3. Independent Pharmacies & Drug Stores

    11.6. Market Value Forecast by Country, 2020–2025

        11.6.1. U.K.

        11.6.2. Germany

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Russia

        11.6.7. Rest of Europe

    11.7. Market Attractiveness Analysis 

        11.7.1. By Disease Indication 

        11.7.2. By Therapeutic Class 

        11.7.3. By Product Type 

        11.7.4. By Distribution Channels 

        11.7.5. By Country

12. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

        12.1.2. Policies and Regulations

        12.1.3. Key Trends

    12.2. Market Value Forecast by Disease Indication, 2020–2025

        12.2.1. Dry Eye

        12.2.2. Glaucoma

        12.2.3. Infection/Inflammation

        12.2.4. Retinal Disorders

            12.2.4.1. Wet AMD

            12.2.4.2. Dry AMD

            12.2.4.3. Diabetic Retinopathy

            12.2.4.4. Others

        12.2.5. Allergy

        12.2.6. Uveitis

        12.2.7. Others

    12.3. Market Value Forecast by Therapeutic Class, 2020–2025

        12.3.1. Anti-inflammatory Drugs

            12.3.1.1. NSAID

            12.3.1.2. Steroids

        12.3.2. Anti-infective Drugs

            12.3.2.1. Anti-fungal Drugs

            12.3.2.2. Anti-bacterial Drugs

            12.3.2.3. Others

        12.3.3. Anti-glaucoma Drugs

            12.3.3.1. Alpha Agonist

            12.3.3.2. Beta Blockers

            12.3.3.3. Prostaglandin Analogs

            12.3.3.4. Combined Medication

            12.3.3.5. Others

        12.3.4. Anti-allergy Drugs

        12.3.5. Anti-VEGF Agents

        12.3.6. Others

    12.4. Market Value Forecast by Product Type, 2020–2025

        12.4.1. Prescription Drugs

        12.4.2. OTC Drugs

    12.5. Market Value Forecast by Distribution Channels, 2020–2025

        12.5.1. Hospital Pharmacies

        12.5.2. Online Pharmacies

        12.5.3. Independent Pharmacies & Drug Stores

    12.6. Market Value Forecast by Country, 2020–2025

        12.6.1. India

        12.6.2. China

        12.6.3. Japan

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis 

        12.7.1. By Disease Indication 

        12.7.2. By Therapeutic Class 

        12.7.3. By Product Type 

        12.7.4. By Distribution Channels 

        12.7.5. By Country

13. Latin America Ophthalmic Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

        13.1.2. Policies and Regulations

        13.1.3. Key Trends

    13.2. Market Value Forecast by Disease Indication, 2020–2025

        13.2.1. Dry Eye

        13.2.2. Glaucoma

        13.2.3. Infection/Inflammation

        13.2.4. Retinal Disorders

            13.2.4.1. Wet AMD

            13.2.4.2. Dry AMD

            13.2.4.3. Diabetic Retinopathy

            13.2.4.4. Others

        13.2.5. Allergy

        13.2.6. Uveitis

        13.2.7. Others

    13.3. Market Value Forecast by Therapeutic Class, 2020–2025

        13.3.1. Anti-inflammatory Drugs

            13.3.1.1. NSAID

            13.3.1.2. Steroids

        13.3.2. Anti-infective Drugs

            13.3.2.1. Anti-fungal Drugs

            13.3.2.2. Anti-bacterial Drugs

            13.3.2.3. Others

        13.3.3. Anti-glaucoma Drugs

            13.3.3.1. Alpha Agonist

            13.3.3.2. Beta Blockers

            13.3.3.3. Prostaglandin Analogs

            13.3.3.4. Combined Medication

            13.3.3.5. Others

        13.3.4. Anti-allergy Drugs

        13.3.5. Anti-VEGF Agents

        13.3.6. Others

    13.4. Market Value Forecast by Product Type, 2020–2025

        13.4.1. Prescription Drugs

        13.4.2. OTC Drugs

    13.5. Market Value Forecast by Distribution Channels, 2020–2025

        13.5.1. Hospital Pharmacies

        13.5.2. Online Pharmacies

        13.5.3. Independent Pharmacies & Drug Stores

    13.6. Market Value Forecast by Country, 2020–2025

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis 

        13.7.1. By Disease Indication 

        13.7.2. By Therapeutic Class 

        13.7.3. By Product Type 

        13.7.4. By Distribution Channels 

        13.7.5. By Country

14. Middle East and Africa Ophthalmic Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

        14.1.2. Policies and Regulations

        14.1.3. Key Trends

    14.2. Market Value Forecast by Disease Indication, 2020–2025

        14.2.1. Dry Eye

        14.2.2. Glaucoma

        14.2.3. Infection/Inflammation

        14.2.4. Retinal Disorders

            14.2.4.1. Wet AMD

            14.2.4.2. Dry AMD

            14.2.4.3. Diabetic Retinopathy

            14.2.4.4. Others

        14.2.5. Allergy

        14.2.6. Uveitis

        14.2.7. Others

    14.3. Market Value Forecast by Therapeutic Class, 2020–2025

        14.3.1. Anti-inflammatory Drugs

            14.3.1.1. NSAID

            14.3.1.2. Steroids

        14.3.2. Anti-infective Drugs

            14.3.2.1. Anti-fungal Drugs

            14.3.2.2. Anti-bacterial Drugs

            14.3.2.3. Others

        14.3.3. Anti-glaucoma Drugs

            14.3.3.1. Alpha Agonist

            14.3.3.2. Beta Blockers

            14.3.3.3. Prostaglandin Analogs

            14.3.3.4. Combined Medication

            14.3.3.5. Others

        14.3.4. Anti-allergy Drugs

        14.3.5. Anti-VEGF Agents

        14.3.6. 14.3.6. Others

    14.4. Market Value Forecast by Product Type, 2020–2025

        14.4.1. Prescription Drugs

        14.4.2. OTC Drugs

    14.5. Market Value Forecast by Distribution Channels, 2020–2025

        14.5.1. Hospital Pharmacies

        14.5.2. Online Pharmacies

        14.5.3. Independent Pharmacies & Drug Stores

    14.6. Market Value Forecast by Country, 2020–2025

        14.6.1. South Africa

        14.6.2. GCC Countries

        14.6.3. Rest of Middle East and Africa

    14.7. Market Attractiveness Analysis 

        14.7.1. By Disease Indication 

        14.7.2. By Therapeutic Class 

        14.7.3. By Product Type 

        14.7.4. 14.7.4. By Distribution Channels 

        14.7.5. 14.7.5. By Country

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis by Company (2018)

    15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

        15.3.1. Aerie Pharmaceuticals, Inc. 

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. ALLERGAN

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Valeant Pharmaceuticals International, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Bayer AG 

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. Novartis AG 

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Pfizer Inc. 

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Regeneron Pharmaceuticals, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview 

        15.3.9. Santen Pharmaceutical Co., Ltd. 

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. Shire

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

            15.3.10.6. Others

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Opthalmic Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025